TaiwanJ Pharmaceuticals Co., Ltd.

Taipei Exchange 6549.TWO

TaiwanJ Pharmaceuticals Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -102.25

TaiwanJ Pharmaceuticals Co., Ltd. Price to Earnings Ratio (P/E) is -102.25 on January 14, 2025, a 24.78% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • TaiwanJ Pharmaceuticals Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is -96.09 on December 24, 2024, which is 6.03% above the current Price to Earnings Ratio (P/E).
  • TaiwanJ Pharmaceuticals Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is -138.62 on August 26, 2024, which is -35.57% below the current Price to Earnings Ratio (P/E).
  • TaiwanJ Pharmaceuticals Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -121.20.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Taipei Exchange: 6549.TWO

TaiwanJ Pharmaceuticals Co., Ltd.

CEO Mr. Hung-Chang Yuan
IPO Date Oct. 21, 2015
Location
Headquarters No.2 ShengYi Road
Employees 12
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email